EGFR and lung carcinoma: Nevertheless, the presence of DLL3 expression in neuroendocrine-transformed tissue and the case studies support further investigation of a DLL3-targeting agent and EGFR TKI in neuroendocrine-transformed EGFR-mutant lung cancer.